Do you want to read an article? Please log in or register.
Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer
Genitourinary Cancer
Related content
Genitourinary Cancer
Updated Findings Support Enfortumab Vedotin plus Pembrolizumab as Standard of Care in Advanced Urothelial Cancer
Genitourinary Cancer
Enfortumab vedotin plus pembrolizumab in treatment-naïve metastatic urothelial carcinoma patients: An Austrian real-world analysis
Int J Cancer
Niedersuess-Beke D, Mayrhofer K, Krauter J, Franke J, Vais D, Pallauf M, Kiesl D, Luger F, Pfuner J, Terbuch A, Bauernhofer T, Spielgelberg J, Banner A, Aufderklamm S, Wiesinger C, Schnabel S, Gampenrieder SP, Mühlmann J, Vallet S, Weibrecht S, Stoiber F, Andalibi H, Fajkovic H, Taghizadeh H, Miechowiecki J, Taedcke R, Heintel D, Shariat SF, Pichler M, Hilbe W, Pichler R
doi: 10.1002/ijc.70203
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Genitourinary Cancer
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study
Lancet Oncol
Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Moreno BH, Beaumont JL, Purnajo I, McManus S, Powles T
doi: 10.1016/S1470-2045(25)00158-5
SPECIAL REPORT
Breast Cancer
Managing Side Effects in Breast Cancer Treatment
RECOMMENDED
Further Publications
Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants for Extended Secondary Venous Thromboembolism Prophylaxis in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Trials
★ 2
Recommended by
Dr Andreas Müller, Faculty Member
Am J Hematol
Mahmoud A, Eltaher B, Shah P, Vengilote R, Mostafa M, Afzal A, Sanfilippo KM
doi: 10.1002/ajh.70090
Genitourinary Cancer
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
N Engl J Med
Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, Niu H, Li J, Shi Y, Yao K, Hu B, Liu Z, Liao H, Yu Z, Jin B, Zhao P, Yang T, Liu X, Qin Y, Xue X, Gou X, Huang J, Gu J, Qi X, Zhang L, Ma G, Liu B, Fang J, Jiang S, He Z, Zhou A, Guo J, RC48-C016 Trial Investigators
doi: 10.1056/NEJMoa2511648
SABCS 2024
Breast Cancer
Advancing Breast Cancer Treatment with Elacestrant
Breast Cancer
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer
Eur J Cancer
Milano M, Valenza C, Ferrari A, Gandini S, Trapani D, Santoro C, Battaiotto E, Carnevale Schianca A, Giordano E, Katrini J, Castellano G, Taurelli Salimbeni B, Leonardi MC, Dicuonzo S, Criscitiello C, Bianco N, Dellapasqua S, Munzone E, Curigliano G, Colleoni M, Jereczek-Fossa BA
doi: 10.1016/j.ejca.2024.115164